Beyond skeletal-related events


Kirkali Z.

EUROPEAN UROLOGY SUPPLEMENTS, vol.5, no.7, pp.553-555, 2006 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 5 Issue: 7
  • Publication Date: 2006
  • Doi Number: 10.1016/j.eursup.2006.02.029
  • Journal Name: EUROPEAN UROLOGY SUPPLEMENTS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.553-555
  • Keywords: antitumor, clinical trials, preclinical, prostate cancer, zoledronic acid, IN-VITRO, BISPHOSPHONATES, PROSTATE, BONE
  • Dokuz Eylül University Affiliated: No

Abstract

Objectives: Zoledronic acid may have potential antitumor activity; it is the most active agent among the bisphosphonates in blocking the prenylation (activation) of small signaling proteins required for cell function and survival. This presentation discusses the results of preclinical studies evaluating the antitumor activity of zoledronic acid and discusses initiated clinical studies.